Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial

Journal of Cystic Fibrosis

Volumn 9, Issue 1, 2010, Pages 17-23

  Kabra, S K ^a   Pawaiya, R ^a   Lodha, Rakesh ^a   Kapil, Arti ^a   Kabra, Madhulika ^a   Vani, A Satya ^a   Agarwal, G ^a   Shastri, S S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Azithromycin; Clinical scores; Cystic fibrosis; FEV1

Indexed keywords

ALPHA TOCOPHEROL; AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BRONCHODILATING AGENT; CEFTAZIDIME; PANCREAS ENZYME; RETINOL; STEROID; VITAMIN D;

ARTICLE; BACTERIAL COLONIZATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TOLERABILITY; ENZYME REPLACEMENT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PEDIATRIC PHYSIOTHERAPY; POSTURAL DRAINAGE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BODY WEIGHT; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-8; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPIROMETRY; SPUTUM; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 73449113632     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2009.09.001     Document Type: Article

References (21)

1. Armstrong D.S., Grimwood K., Carzino R., Carlin J.B., Olinsky A., and Phelan P.D. Lower respiratory tract infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 310 (1995) 1571-1572
2. Kahn T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., and Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151 (1995) 1075-1082
3. Konstan M.W., Hilliard K.A., Norvell T.M., and Berger M. Broncho alveolar lavage findings in cystic fibrosis patients with stable clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 150 (1994) 448-454
4. Jaffé A., and Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 31 (2001) 464-473
5. Wolter J., Seeney S., Bell S., Bowler S., Masel P., and McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 57 (2002) 212-216
6. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
7. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
8. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., and Jais J.P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61 (2006) 895-902
9. McCormack J., Bell S., Senini S., Walmsley K., Patel K., Wainwright C., et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 30 (2007) 487-495
10. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardization of spirometry. Eur Respir J 26 (2005) 319-338
11. Kabra S.K., Alok A., Kapil A., Aggarwal G., Kabra M., Lodha R., et al. Can throat swab after physiotherapy replace sputum or cough swab for identification of microbial pathogens in children with cystic fibrosis?. Indian J Pediatr 71 (2004) 15-20
12. Shwachman H. Cystic fibrosis. In: Kendig E.L., and Chernick V. (Eds). Disorders of respiratory tract in children. 4th edition (1983), WB Sounders, London 640-661
13. Govan J.R.W. Pseudomonas, Stenotrophomonas, Burkholdelia. In: Collee J.G., Fraser A.G., Marmion B.P., and Simmons A. (Eds). Mackie and McCarttney Practical Medical Microbiology. th edn vol. 14 (1996), Churchill Livingstone, New York 413-424
14. Jaffé A., Francis J., Rosenthal M., and Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351 (1998) 420
15. Osika E., Cavillon J.M., Chadelat K., Boule M., Fitting C., Tournier G., et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. J Eur Respir 14 (1999) 339-346
16. Baumann U., King M., App E.M., Tai S., König A., Fischer J.J., et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can Respir J 11 (2004) 151-155
17. Southern K.W., Barker P.M., and Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 3 (2003) CD002203
18. Steinkamp G., Schmitt-Grohe S., Döring G., Staab D., Pfründer D., Beck G., et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 102 (2008) 1643-1653
19. Saiman L., Mayer-Hamblett N., Campbell P., Marshall B.C., and Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 172 (2005) 1008-1012
20. Murray T.S., Egan M., and Kazmierczak B.I. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 19 (2007) 83-88
21. Cigana C., Assael B.M., and Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 51 (2007) 975-981